<\/b><\/p>\n
<\/b><\/p>\n
MONDAY, May 21, 2018 (HealthDay News) — Airway bioengineering appears feasible for tracheal and bronchial reconstruction, according to a study published online May 20 in the Journal of the American Medical Association<\/i> to coincide with the American Thoracic Society’s 2018 International Conference, held from May 18 to 23 in San Diego.<\/p>\n
Emmanuel Martinod, M.D., Ph.D., from the H\u00f4pitaux Universitaires Paris Seine-Saint Denis, and colleagues recruited 20 patients with end-stage tracheal lesions or with proximal lung tumors requiring a pneumonectomy. Standard surgical techniques were used to perform radical resection of the lesions; airway reconstruction was performed after resection using a human cryopreserved aortic allograft. A custom made stent was inserted into the allograft to prevent airway collapse.<\/p>\n
Thirteen patients underwent tracheal, bronchial, or carinal transplantation; in seven patients, airway transplantation was not performed. The researchers found that the 90-day mortality rate was 5 percent among the 20 patients. Patients who underwent tracheal or bronchial reconstruction had no mortality at 90 days. Major 90-day morbidity events occurred in four of the 13 patients who underwent airway transplantation. At a postoperative mean of 18.2 months, stent removal was performed. Ten of the 13 patients were alive at a median follow-up of three 3 years 11 months; eight of these breathed normally through airways newly formed after stent removal.<\/p>\n
“Airway bioengineering using stented aortic matrices demonstrated feasibility for complex tracheal and bronchial reconstruction,” the authors write.<\/p>\n
Several authors disclosed financial ties to the pharmaceutical industry.<\/p>\n
Abstract\/Full Text<\/a><\/p>\n Editorial<\/a><\/p>\n